Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eugenia Mato is active.

Publication


Featured researches published by Eugenia Mato.


Autoimmunity | 1999

IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in Genetic Susceptibility to Type 1 Diabetes (Insulin-dependent)

Z. M. Larsen; O. P. Kristiansen; Eugenia Mato; Jesper Johannesen; Manuel Puig-Domingo; Alberto de Leiva; Jørn Nerup; Flemming Pociot

Type 1 diabetes (insulin-dependent) is a multifactorial disease with polygenic susceptibility. The major genetic component (IDDM1) resides within the HLA region, but several non-HLA loci have been implicated in the genetic susceptibility. In the present study, we have analysed two such loci, IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34, in Danish (n = 254) and Spanish (n = 39) type 1 diabetic multiplex families. No significant evidence of linkage of IDDM12 was observed in any of the two studied data sets. However, when the present data were combined with previously published data, they strengthened the evidence of linkage at this locus, p = 0.00002. For the IDDM13 region, we found some positive evidence of linkage of the D2S137-D2S164-D2S1471 markers (p-values 0.007, 0.02, and 0.007, respectively) using transmission disequilibrium testing (TDT) and the Tsp version of the TDT. Importantly, random transmission of all tested alleles was observed in unaffected offspring (p > 0.3). Stratification for HLA (high risk and non-high risk genotypes) in the Danish families did not reveal heterogeneity at IDDM12 or IDDM13. In conclusion, our data on an entirely new family data set did not support the existence of IDDM12 as a type 1 diabetes susceptibility locus in the Danish population. In addition, we found support for evidence of linkage and association of the IDDM13/D2S137-D2S1471 region (approximately 3.5 cM) to type 1 diabetes, however, further studies are needed to substantiate this observation.


European Journal of Nuclear Medicine and Molecular Imaging | 1998

Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma

Lluis Berná; Ana Chico; Xavier Matias-Guiu; Eugenia Mato; Ana M. Catafau; Carmen Alonso; Josefina Mora; Didac Mauricio; José Rodríguez-Espinosa; Carina Mari; Albert Flotats; Juan-Carlos Martín; Montserrat Estorch; Ignasi Carrió

Abstract.Detection of recurrence of medullary thyroid carcinoma (MTC) remains a diagnostic problem. Increased serum tumour marker levels frequently indicate recurrence while conventional imaging techniques (CIT) are non-diagnostic. In this study, we performed indium-111 octreotide scintigraphy and CIT in a series of 20 patients with MTC presenting with elevated serum tumour markers after surgery. 111In-octreotide whole-body studies detected 15 pathological uptake foci in 11 of the 20 patients studied and CIT detected 17 lesions in 11 of the 20 patients. Ten patients underwent reoperation, five of them with positive 111In-octreotide scintigraphy and CIT and two with positive isotopic exploration and negative CIT. Surgical findings demonstrated that the results of isotopic study and CIT had been false-positive for MTC in one case (sarcoidosis). The six patients with true-positive 111In-octreotide studies had significantly higher basal calcitonin (CT) and carcinoembryonic antigen (CEA) levels than the patients with negative isotopic studies. The expression of somatostatin receptor (SSTR) subtypes by PC-PCR could be investigated in four cases with a positive isotopic study. Among the three cases with a true-positive study, SSTR2, the SSTR subtype that preferentially binds to the somatostatin analogue octreotide, was detected in two, SSTR5 was demonstrated in the three, and SSTR3 was detected in one. No subtype of SSTR was detected in the case with a final diagnosis of sarcoidosis. We conclude that 111In-octreotide has limited sensitivity in detecting recurrence in patients with MTC, although its sensitivity may improve with high serum CT levels. This radionuclide imaging technique should be employed when conventional imaging techniques are negative or inconclusive or when the presence of somatostatin receptors may provide the basis for treatment with somatostatin analogues.


Journal of Molecular Medicine | 1998

A novel germline mutation in exon 5 of the multiple endocrine neoplasia type 1 gene

Ana Chico; Luis Gallart; Eugenia Mato; Carmen Mayoral; Jesús M. Martín-Campos; Lluis Catasus; José Rodríguez-Espinosa; Xavier Matias-Guiu; Francisco Blanco-Vaca; Alberto de Leiva

Abstract The autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by neoplasia of parathyroids, anterior pituitary, and gastrointestinal and pancreatic neuroendocrine tissues. Recently the gene responsible for the MEN1 syndrome has been identified on chromosome region 11q13. Most of the described mutations are nucleotide substitutions and small deletions affecting exons 2 and 3, causing protein truncation. Only one mutation in exon 5 has been found, and this corresponds to a MEN1 sporadic case. Small insertions are also rare. We studied a MEN1 family composed of five members, two of whom were clinically affected. We found a new germline 1 basepair insertional mutation affecting the exon 5 of the MEN1 gene in the two members affected in this MEN1 family.


Journal of Pineal Research | 1993

Expression of somatostatin in rat pineal cells in culture

Eugenia Mato; Pilar Santisteban; M. Viader; G. Capellá; Oscar Fornas; Manuel Puig-Domingo; Susan M. Webb

Abstract: The expression of somatostatin mRNA was investigated in rat pineal cells after 1 week in culture, using reverse transcription of mRNA into cDNA and the polymerase chain reaction. The positive expression in cultured pineal cells demonstrates the capacity of this gland to synthesize somatostatin in denervated cells. Thus, apart from the neural origin of pineal somatostatin, which has been described in detail in the bovine species, a parenchymal source is demonstrated.


European Journal of Endocrinology | 2014

Telomere length analysis in Cushing's syndrome

Anna Aulinas; María-José Ramírez; María-José Barahona; Elena Valassi; Eugenia Resmini; Eugenia Mato; Alicia Santos; Iris Crespo; Olga Bell; Jordi Surrallés; Susan M. Webb

INTRODUCTION Hypercortisolism in Cushings syndrome (CS) is associated with increased morbidity and mortality. Hypercortisolism also occurs in chronic depressive disorders and stress, where telomere length (TL) is shorter than in controls. We hypothesized that shortening of telomere might occur in CS and contribute to premature aging and morbidity. AIM To investigate TL in CS patients compared with controls. METHODS Seventy-seven CS patients (14 males, 59 pituitary, 17 adrenal, and one ectopic; 21 with active disease) were compared with 77 gender-, age-, and smoking-matched controls. Fifteen CS were evaluated longitudinally, during active disease and after remission of hypercortisolism. Leukocyte TL was measured by telomere restriction fragment-Southern technique. Clinical markers were included in a multiple linear regression analysis to investigate potential predictors of TL. RESULTS Mean TL in CS patients and controls was similar (7667 vs 7483 bp, NS). After adjustment for age, in the longitudinal evaluation, TL was shorter in active disease than after remission (7273 vs 7870, P<0.05). Age and dyslipidemia were negative predictors (P<0.05), and total leukocyte count was a positive predictor for TL (P<0.05). As expected, a negative correlation was found between TL and age (CS, R=-0.400 and controls, R=-0.292; P<0.05). No correlation was found between circulating cortisol, duration of exposure to hypercortisolism or biochemical cure and TL. CONCLUSION Even though in the cross-sectional comparison of CS and controls no difference in TL was found, in the longitudinal evaluation, patients with active CS had shorter TL than after biochemical cure of hypercortisolism. These preliminary results suggest that hypercortisolism might negatively impact telomere maintenance. Larger studies are needed to confirm these findings.


Clinical Endocrinology | 2013

Telomeres and endocrine dysfunction of the adrenal and GH/IGF-1 axes

Anna Aulinas; M.J. Ramírez; María José Barahona; Eugenia Mato; Olga Bell; Jordi Surrallés; Susan M. Webb

Telomeres, located at the end of linear chromosomes, are essential to maintain genomic stability. Telomere biology has recently emerged as an important player in the fields of ageing and disease. To maintain telomere length (TL) and reduce its degradation after mitosis, the telomerase enzyme complex is produced. Genetic, epigenetic, hormonal and environmental factors can regulate telomerase function. These include stress hormones such as cortisol and growth factors. The hypothalamic–pituitary–adrenal (HPA) axis has been evaluated in psychiatric diseases where hypercortisolism and oxidative stress are often present. Some researches have linked TL shortening to increases in stress‐related cortisol, but others have not. The effects of cortisol on the telomere system are complex and may depend on the intensity and duration of exposure. On the other hand, low levels of IGF‐1 are associated with inflammation and ageing‐related diseases (ischaemic heart disease, congestive heart failure). Both IGF‐1 and TL diminish with age and are positively and strongly correlated with each other. It is not clear whether this positive correlation reflects a single association or a cause–effect relationship. Further research will ideally investigate longitudinal changes in telomeres and both these hormonal axes. To our knowledge, TL dysfunction has not been described in either endogenous hypercortisolism (Cushings syndrome) or acromegaly where excessive amounts of GH and consequently IGF‐1 are produced. This review focuses on the possible relationships between telomere dysfunction and the hypothalamic–pituitary–adrenal (HPA) axis and GH‐IGF‐1 system.


Neuroendocrinology | 1997

Circannual Somatostatin Gene and Somatostatin Receptor Gene Expression in the Early Post-Natal Rat Pineal Gland

Eugenia Mato; Pilar Santisteban; Julie A. Chowen; Oscar Fornas; Martijn Bouwens; Manel Puig-Domingo; Jesús Argente; Susan M. Webb

The origin of somatostatin in the pineal gland is controversial as a double origin - neural in pinealopetal nerve fibers and parenchymal corresponding to locally synthesized peptide - is suggested. We have investigated the ontogeny and possible circadian and circannual variations of somatostatin and somatostatin receptor gene expression in the rat pineal gland using RT-PCR. Somatostatin gene expression was observed in the pineal of animals up to 15 days of postnatal life in autumn and winter, but not in prepubertal or adult rats; no transcript was detected during spring and summer at any age and a circadian rhythm was only detected in 15-day-old rats. In situ hybridization confirmed these results. The transcript of the somatostatin receptor gene (SSTR2) was detected at all ages studied with no seasonal variations in its expression, indicating separate regulatory mechanisms. In conclusion, somatostatin and somatostatin receptor mRNAs are expressed in the neonatal rat pineal with circadian and seasonal variations.


Clinical Endocrinology | 2014

Thyroglobulin as early prognostic marker to predict remission at 18–24 months in differentiated thyroid carcinoma

Cintia Gonzalez; Anna Aulinas; Cristina Colom; Diana Tundidor; Lilian Mendoza; Rosa Corcoy; Eugenia Mato; Valeria Alcántara; Eulalia Urgell Rull; Alberto de Leiva

Thyroglobulin (Tg), the most common marker to determine remission of differentiated thyroid carcinoma (DTC), can take 18 months or longer to be undetectable. We hypothesized that Tg stimulated after surgery and immediately before radioiodine treatment (baseline‐stimulated Tg) could be a good predictor of remission at 18–24 months. The aim of this study was to evaluate the role of baseline‐stimulated Tg as early prognostic marker of DTC.


PLOS ONE | 2015

Dyslipidemia and Chronic Inflammation Markers Are Correlated with Telomere Length Shortening in Cushing’s Syndrome

Anna Aulinas; María-José Ramírez; María-José Barahona; Elena Valassi; Eugenia Resmini; Eugenia Mato; Alicia Santos; Iris Crespo; Olga Bell; Jordi Surrallés; Susan M. Webb

Introduction Cushing’s syndrome (CS) increases cardiovascular risk (CVR) and adipocytokine imbalance, associated with an increased inflammatory state. Telomere length (TL) shortening is a novel CVR marker, associated with inflammation biomarkers. We hypothesized that inflammatory state and higher CVR in CS might be related to TL shortening, as observed in premature aging. Aim To evaluate relationships between TL, CVR and inflammation markers in CS. Methods In a cross-sectional study, 77 patients with CS (14 males, 59 pituitary-, 17 adrenal- and 1 ectopic-origin; 21 active disease) and 77 age-, gender-, smoking-matched controls were included. Total white blood cell TL was measured by TRF-Southern technique. Clinical data and blood samples were collected (lipids, adrenal function, glucose). Adiponectin, interleukin-6 (IL6) and C-reactive protein (CRP) were available in a subgroup of patients (n=32). Correlations between TL and clinical features were examined and multiple linear regression analysis was performed to investigate potential predictors of TL. Results Dyslipidemic CS had shorter TL than non-dyslipidemic subjects (7328±1274 vs 7957±1137 bp, p<0.05). After adjustment for age and body mass index, cured and active CS dyslipidemic patients had shorter TL than non-dyslipidemic CS (cured: 7187±1309 vs 7868±1104; active: 7203±1262 vs 8615±1056, respectively, p<0.05). Total cholesterol and triglycerides negatively correlated with TL (r-0.279 and -0.259, respectively, p<0.05), as well as CRP and IL6 (r-0.412 and -0.441, respectively, p<0.05). No difference in TL according the presence of other individual CVR factors (hypertension, diabetes mellitus, obesity) were observed in CS or in the control group. Additional TL shortening was observed in dyslipidemic obese patients who were also hypertensive, compared to those with two or less CVR factors (6956±1280 vs 7860±1180, respectively, p<0.001). Age and dyslipidemia were independent negative predictors of TL. Conclusion TL is shortened in dyslipidemic CS patients, further worse if hypertension and/or obesity coexist and is negatively correlated with increased inflammation markers. Increased lipids and a “low” grade inflammation may contribute to TL shortening and consequently to premature ageing and increased morbidity in CS.


Journal of diabetes science and technology | 2013

PREDIRCAM eHealth Platform for Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity, Diabetes, and Cardiometabolic Risk Prevention: A Pilot Study (PREDIRCAM 1 >

Cintia Gonzalez; Pau Herrero; José María Cubero; José M. Iniesta; M. Elena Hernando; Gema García-Sáez; Alvaro Serrano; Iñaki Martínez-Sarriegui; Carmen Pérez-Gandía; Enrique J. Gómez; Esther Rubinat; Valeria Alcántara; Eulalia Brugués; Ana Chico; Eugenia Mato; Olga Bell; Rosa Corcoy; Alberto de Leiva

Background: Healthy diet and regular physical activity are powerful tools in reducing diabetes and cardiometabolic risk. Various international scientific and health organizations have advocated the use of new technologies to solve these problems. The PREDIRCAM project explores the contribution that a technological system could offer for the continuous monitoring of lifestyle habits and individualized treatment of obesity as well as cardiometabolic risk prevention. Methods: PREDIRCAM is a technological platform for patients and professionals designed to improve the effectiveness of lifestyle behavior modifications through the intensive use of the latest information and communication technologies. The platform consists of a web-based application providing communication interface with monitoring devices of physiological variables, application for monitoring dietary intake, ad hoc electronic medical records, different communication channels, and an intelligent notification system. A 2-week feasibility study was conducted in 15 volunteers to assess the viability of the platform. Results: The website received 244 visits (average time/session: 17 min 45 s). A total of 435 dietary intakes were recorded (average time for each intake registration, 4 min 42 s ± 2 min 30 s), 59 exercises were recorded in 20 heart rate monitor downloads, 43 topics were discussed through a forum, and 11 of the 15 volunteers expressed a favorable opinion toward the platform. Food intake recording was reported as the most laborious task. Ten of the volunteers considered long-term use of the platform to be feasible. Conclusions: The PREDIRCAM platform is technically ready for clinical evaluation. Training is required to use the platform and, in particular, for registration of dietary food intake.

Collaboration


Dive into the Eugenia Mato's collaboration.

Top Co-Authors

Avatar

Susan M. Webb

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Alberto de Leiva

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Ana Chico

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Olga Bell

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Xavier Matias-Guiu

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Anna Aulinas

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Carmen Mayoral

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Elena Valassi

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Eugenia Resmini

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Iris Crespo

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge